China Begins Clinical Studies on Anti-Viral Drug to Combat Bird Flu
Posted on: Sunday, 19 March 2006, 09:00 CST
China begins clinical studies on anti-viral drug to combat bird flu
BEIJING, March 18 (Xinhua) -- The Chinese government has given the go-ahead to a Shanghai-based pharmaceutical firm to begin clinical studies on the effectiveness of Tamiflu, an anti-viral drug that is believed to be the best form of defense against bird flu in humans.
The drug will be manufactured by Shanghai Sunve Pharmaceutical Co., Ltd under a licensing arrangement with Swiss drug producer Roche. The study will seek to establish if the Tamiflu produced by the Shanghai firm is as effective as that produced by Roche.
Tamiflu is made from shikimic acid, which is found in star anise, often used as a spice in Chinese cooking.
Sunve is a company affiliated to the Shanghai Pharmaceutical Group Co., Ltd., which has been licensed by Roche to produce Tamiflu in China.
Source: Xinhua News Agency - CEIS
Related Articles
- Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) From Valeant Pharmaceuticals
- Flu Drug Tamiflu Fares Well in Testing
- Chinese Company Granted Right to Produce Anti-Influenza Drug Tamiflu
- Indonesia to Make Bird Flu Drug Tamiflu
- Indonesia says will make anti-viral drug Tamiflu
- Side Effects of Flu Drug Tamiflu Under Investigation
- US reviewing deaths, mental effects of drug Tamiflu
- Antiviral Flu Drug Tamiflu Nearly Runs Out in Bulgaria Amid Avian Flu Panic
- Scientists Find Avian Flu Virus Resistant to Drug Tamiflu
- Bird Flu Virus Found Resistant to Antiviral Drug Tamiflu in Vietnamese Patient
 |
 |
User Comments (0)
RSS Feeds